Highlights

  • ResMed Inc (ASX:RMD) traded at $27.54, down 0.76%, at the time of writing on 23 July 2026.
  • The stock is 32.70% lower over the past year.
  • The S&P/ASX 200 Health Care (ASX:XHJ) Index was trading at 25,440.40 points, declined 1.43%, during the session.
  • ResMed Inc has a market capitalisation of approximately AUD 16.36 billion.

ResMed Inc (ASX:RMD) traded at $27.54, down 0.76%, at the time of writing on 23 July 2026. The stock is 32.70% lower over the past year. At the time of writing on 23 July 2026, the S&P/ASX 200 Health Care (ASX:XHJ) Index was trading at 25,440.40 points, declined 1.43% during the session, while the broader S&P/ASX 200 (ASX:XJO) stood at 8,839.00 points, edging up marginally during the same period.

With a market capitalisation of approximately AUD 16.36 billion, ResMed Inc is among the companies reflected in the S&P/ASX 200 Health Care Index, which tracks major healthcare-related businesses listed on the Australian Securities Exchange.

Although the shares recorded a notable move during the session, daily price movements should not automatically be interpreted as changes in the company's underlying business performance. Equity prices can fluctuate due to investor sentiment, sector-wide movements, macroeconomic developments and broader market conditions, even in the absence of company-specific developments.

Business Overview

ResMed Inc is a global medical device and software company headquartered in San Diego, California, specialising in the diagnosis, treatment and management of sleep apnoea, respiratory failure and related conditions. The company manufactures continuous positive airway pressure (CPAP) devices, masks and accessories, and has expanded significantly into cloud-connected digital health, with its AirSense device range and myAir patient engagement platform serving millions of patients globally. ResMed is primary listed on the New York Stock Exchange and also has a CHESS Depositary Interest listing on the ASX.

Industry Position

The global sleep apnoea device market continues to benefit from growing awareness and diagnosis rates for obstructive sleep apnoea, a condition estimated to affect hundreds of millions of adults worldwide but significantly under-diagnosed. The competitive landscape has evolved in recent years with the emergence of GLP-1 weight-loss medications, which some clinicians believe may reduce the severity of sleep apnoea in certain patient groups, introducing a long-term structural question the market continues to assess.

During the afternoon trading session on 23 July 2026, the S&P/ASX 200 Health Care (ASX:XHJ) Index declined 1.43%, indicating broader weakness across listed healthcare companies. While sector performance provides useful market context, investors generally continue evaluating healthcare companies based on clinical progress, commercial execution, regulatory developments and long-term strategic positioning.

What Investors Watch

For healthcare companies such as ResMed, investors typically assess a range of operational and financial indicators beyond short-term share price movements.

For medical device companies such as ResMed, investors typically monitor device shipment volumes and revenue growth, the uptake of software and digital health subscriptions which carry higher margins, competitive dynamics including the potential impact of GLP-1 medications on addressable market size, mask and accessory revenue as a recurring consumable stream, and the performance of the Software as a Medical Device portfolio including its resolutions and Brightree businesses.

Regulatory developments, pipeline milestones, commercial execution and balance sheet strength are additional areas that investors frequently evaluate when assessing prospects within the healthcare sector.

Understanding Share Price Movements

Daily fluctuations in share prices are a normal feature of financial markets and should be interpreted within a broader investment context.

A one-day decline does not necessarily indicate a change in a company's underlying business, just as a single day's move does not automatically imply improving or deteriorating fundamentals. Market movements can reflect changes in investor expectations, sector sentiment, institutional positioning and macroeconomic developments.

Investors generally consider clinical and commercial progress, regulatory milestones, revenue growth and competitive positioning alongside market valuations when evaluating healthcare companies.

Long-Term Perspective

Healthcare companies operate in industries shaped by scientific innovation, regulatory frameworks, demographic trends and evolving clinical practice.

Sleep health device companies operate in a market shaped by rising diagnosis rates, digital connectivity and evolving clinical pathways. For companies such as ResMed, long-term performance is frequently evaluated through device placement growth, digital health subscription adoption, mask consumable revenue trends and the ability to navigate evolving competitive and clinical dynamics.

Healthcare sector valuations can fluctuate significantly as market expectations change, meaning share prices may move independently of near-term operating developments. This highlights the importance of assessing both underlying business fundamentals and broader market conditions when evaluating companies in the healthcare sector.

Final Takeaway

ResMed's shares eased during the afternoon trading session on 23 July 2026, while the broader S&P/ASX 200 Health Care Index also declined. The company continues to operate as one of the world's leading providers of sleep apnoea devices and connected digital health solutions.

While daily share price movements often attract attention, they do not necessarily reflect changes in a company's underlying fundamentals. Investors typically continue monitoring ResMed's business progress, commercial execution and strategic positioning when assessing its long-term outlook within the healthcare sector.